Articles de revue sur le cancer de la prostate - Der nières parutions

InTextoResearch, agence d'information scientifique

InTextoResearch vous informe sur les dernières parutions d'articles
de
revue sur le cancer de la prostate (8 février 2008):

Clinical practice. Localized prostate cancer.
Walsh PC, DeWeese TL, Eisenberger MA.
N Engl J Med. 2007 Dec 27;357(26):2696-705.

ETS transcription factors: oncogenes and tumor suppressor genes as
therapeutic targets for prostate cancer.
Turner DP, Watson DK.
Expert Rev Anticancer Ther. 2008 Jan;8(1):33-42.

Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-
independent prostate cancer.
Patel PH, Kockler DR.
Ann Pharmacother. 2008 Jan;42(1):91-8.

Clinical pharmacology and use of microtubule-targeting agents in
cancer therapy.
Zelnak AB.
Methods Mol Med. 2007;137:209-34.

The role of sargramostim (rhGM-CSF) as immunotherapy.
Waller EK.
Oncologist. 2007;12 Suppl 2:22-6.

Endothelin receptor antagonists in cancer therapy.
Lalich M, McNeel DG, Wilding G, Liu G.
Cancer Invest. 2007 Dec;25(8):785-94.

The role of tissue microarrays in prostate cancer biomarker discovery.
Datta MW, True LD, Nelson PS, Amin MB.
Adv Anat Pathol. 2007 Nov;14(6):408-18.

Role of 5 alpha-reductase inhibitors in the management of prostate
cancer.
Hudak SJ, Hernandez J, Thompson IM.
Clin Interv Aging. 2006;1(4):425-31.

Recent approaches in chemoprevention of prostate cancer.
Young CY.
Curr Cancer Drug Targets. 2007 Nov;7(7):681-8.

GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular
immunotherapy for the treatment of prostate cancer.
Ward JE, McNeel DG.
Expert Opin Biol Ther. 2007 Dec;7(12):1893-902.

Neuroendocrine differentiation in prostate cancer: from lab to
bedside.
Cindolo L, Cantile M, Vacherot F, Terry S, de la Taille A.
Urol Int. 2007;79(4):287-96.

The effect of body mass index on PSA levels and the development,
screening and treatment of prostate cancer.
Skolarus TA, Wolin KY, Grubb RL 3rd.
Nat Clin Pract Urol. 2007 Nov;4(11):605-14.

Gene therapy in prostate cancer: past, present and future.
Shirakawa T, Fujisawa M, Gotoh A.
Front Biosci. 2008 Jan 1;13:2115-9.

Anti-angiogenesis and RGD-containing snake venom disintegrins.
Swenson S, Ramu S, Markland FS.
Curr Pharm Des. 2007;13(28):2860-71.

Clinical proteomics: discovery of cancer biomarkers using mass
spectrometry and bioinformatics approaches--a prostate cancer
perspective.
Matharoo-Ball B, Ball G, Rees R.
Vaccine. 2007 Sep 27;25 Suppl 2:B110-21.

Leuprolide acetate: a drug of diverse clinical applications.
Wilson AC, Meethal SV, Bowen RL, Atwood CS.
Expert Opin Investig Drugs. 2007 Nov;16(11):1851-63.

TMPRSS2-ETS fusion prostate cancer: biological and clinical
implications.
Demichelis F, Rubin MA.
J Clin Pathol. 2007 Nov;60(11):1185-6.

The roles of proteolytic enzymes in the development of tumour-induced
bone disease in breast and prostate cancer.
Woodward JK, Holen I, Coleman RE, Buttle DJ.
Bone. 2007 Dec;41(6):912-27.

Molecular biology of bone metastasis.
Kingsley LA, Fournier PG, Chirgwin JM, Guise TA.
Mol Cancer Ther. 2007 Oct;6(10):2609-17.

Epothilones in prostate cancer: review of clinical experience.
Dawson NA.
Ann Oncol. 2007 Jul;18 Suppl 5:v22-7.


(contact pour InTextoResearch: Marc Lacroix, Baelen, Wallonie,
Belgique - scimed...@mail.com)